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macrophage activation syndrome. In animals, 
high levels of interleukin-6 contribute to the trig-
gering of this syndrome1; additional cytokines, 
including interferon-γ, interleukin-1, and inter-
leukin-18, might be involved in maintaining and 
amplifying the inflammatory response.2 Indeed, 
interleukin-1 antagonism may be beneficial in a 
full-blown case of the macrophage activation 
syndrome.3 Regarding the possible role of toci-
liz umab in masking the symptoms of this syn-
drome, the five patients with the macrophage 
activation syndrome reported by Shimizu et al.4 
had mild laboratory abnormalities representing 
either blunted cases of the macrophage activa-
tion syndrome, possibly consistent with the above-
mentioned role of interleukin-6 in the triggering 
of the syndrome, or part of the known side effects 
of tocilizumab (i.e., increased aminotransferase 
levels and neutropenia). Long-term vigilance on 
the rate and features of the macrophage activa-
tion syndrome during tocilizumab treatment will 
provide additional useful information for clinical 
practice.
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Tolvaptan in Autosomal Dominant Polycystic Kidney Disease
To the Editor: In the Tolvaptan Efficacy and 
Safety in Management of Autosomal Dominant 
Polycystic Kidney Disease and Its Outcome 
(TEMPO) 3:4 trial, Torres et al. (Dec. 20 issue)1 
found that tolvaptan slowed the increase in renal 
volume and the decline in renal function, as com-
pared with placebo, in patients with autosomal 
dominant polycystic kidney disease (ADPKD). 
Given that the beneficial effect of tolvaptan is 
thought to operate through the inhibition of 
V2-receptor activation and the suppression of cy-
clic AMP (cAMP), it seems likely that a similarly 
beneficial effect on the course of ADPKD could 
be achieved with a high fluid intake alone, be-
cause this suppresses vasopressin release and 
cAMP formation.2 Therefore, it is hard to under-
stand why the investigators did not instruct both 
groups to ingest large amounts of water, as two 
of the authors had previously recommended.2 
Had they done so, we would have known whether 
tolvaptan is superior to a high fluid intake alone. 
In view of the worrisome adverse effects of tolvap-
tan seen in the trial, including elevated liver-
enzyme levels, as well as the extremely high cost 
of tolvaptan (cost of daily 90-mg dose >$25,000 
per month3), a monitored high water intake may 
be safer, far cheaper, and equally effective.
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To the Editor: Torres et al. found that tolvaptan 
slowed the decline in kidney function in patients 
with ADPKD. One small, short-term study1 
showed a reversible decline in the glomerular fil-
tration rate (GFR) and an increase of approxi-
mately 8% in the serum creatinine after the ini-
tiation of tolvaptan in patients with ADPKD. 
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Therefore, in the study by Torres et al., the kidney-
function end points were assessed after the dose-
escalation phase was completed.
Did this larger study find a similar effect? 
Before there is widespread use of tolvaptan in 
patients with ADPKD, it would be important for 
practitioners to be aware of the expected average 
and range of the increase in the creatinine level 
after the initiation of tolvaptan and whether this 
would be reversible after 3 years of therapy. Is 
there a percentage increase in creatinine at which 
tolvaptan therapy should be stopped?
It is interesting to note that this effect has 
not been reported when tolvaptan has been used 
in large studies of hyponatremia or heart failure, 
although at lower doses than were used in the 
study by Torres et al. This raises questions about 
whether this is a dose-related effect or whether 
it is specific to ADPKD.
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To the Editor: In a prespecified subgroup 
analysis, tolvaptan had a beneficial effect on total 
kidney volume in all subgroups specified accord-
ing to baseline values for total kidney volume 
(<1500 ml vs. ≥1500 ml).
Ho et al. examined the central and nephro-
genic components of osmoregulation with the 
use of water-deprivation tests in 10 adults and 
10 children with ADPKD and normal renal 
function.1 These patients had a peripheral resis-
tance to vasopressin, the extent of which was 
directly correlated with total kidney volume, as 
assessed on magnetic resonance imaging.
One might hypothesize that if the nephro-
genic resistance to vasopressin is related to total 
kidney volume, then perhaps the beneficial ef-
fects of vasopressin antagonism will be greater 
in patients with a lower total kidney volume at 
the start of treatment, as compared with those 
with a higher total kidney volume, since patients 
with a lower volume may be inherently more 
sensitive to the deleterious effects of vasopres-
sin. Was the slowing of the increase in total 
kidney volume associated with a baseline value 
that was defined as a continuous variable, rather 
than dichotomized into groups (<1500 ml vs. 
≥1500 ml)? One might expect that patients with 
a lower total kidney volume at baseline had a 
greater reduction in the rate of growth in total 
kidney volume, as compared with those with a 
higher total kidney volume at baseline.
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To the Editor: A history of urinary tract infec-
tion is regarded as an independent prognostic fac-
tor for a decline in GFR in patients with ADPKD.1 
Furthermore, evidence indicates substantial over-
lap between biologic processes involved in cysto-
genesis and in kidney injury, with macrophages 
having a key role.2,3 In the TEMPO 3:4 trial, pa-
tients who received tolvaptan had a significantly 
lower rate of urinary tract infection and renal 
cyst infection, as compared with patients who 
received placebo.4 This finding probably reflects 
the importance of polyuria and pollakiuria in 
preventing urinary tract infection.5 On the basis 
of the emerging concept of renal inflammation 
as an essential pathogenic component of natu-
rally progressing cystic kidney disease, we specu-
late that the lower incidence of urinary tract in-
fection and renal cyst infection observed in the 
tolvaptan group contributes to the potential bene-
fit of this drug on the decline in GFR in patients 
with ADPKD. Further prospective trials compar-
ing the use and nonuse of tolvaptan in patients 
with ADPKD with equivalent urinary volume and 
frequency would provide data regarding the pro-
tective effect of tolvaptan per se.
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The Authors Reply: Spital points out that increas-
ing water intake may slow down the progression 
of ADPKD.1 However, adherence to a regimen of 
high water intake that would be sufficient to 
suppress vasopressin during prolonged periods 
of time may be difficult2 and, as some authors 
have suggested, possibly deleterious.3 In the 
TEMPO 3:4 study, all patients were encouraged 
to drink enough water to avoid dehydration. As a 
result, water intake in placebo-treated patients 
increased, as reflected by the reduction of median 
nonfasting first-morning-urine osmolality from 
a baseline value of 511 mOsm per kilogram of 
water (95% confidence interval [CI], 164 to 863) 
to 438 mOsm per kilogram (95% CI, 159 to 792) 
during the trial. A specifically designed clinical 
trial would be necessary to determine whether 
high water intake and tolvaptan are equally effec-
tive treatments. Tolvaptan has not been approved 
for the treatment of ADPKD; therefore, pricing 
information is not available.
Kher raises important questions regarding cre-
atinine levels. The median serum creatinine level 
in the tolvaptan group increased from 1.00 mg per 
deciliter (95% CI, 0.61 to 1.76) to 1.06 mg per 
deciliter (95% CI, 0.64 to 1.88; median change, 
0.05 mg per deciliter [95% CI, −0.14 to 0.30]) 
during the dose-escalation phase and decreased 
from 1.14 mg per deciliter (95% CI, 0.67 to 2.47) 
to 1.08 mg per deciliter (95% CI, 0.63 to 2.33; 
median change, −0.04 mg per deciliter [95% CI, 
−0.32 to 0.16]) during the washout phase. The 
initial, reversible reduction in GFR probably re-
flects the reversal of the dampening effect of 
vasopressin on tubuloglomerular feedback.4 As 
such, it is expected to be dose-related and not 
specific to ADPKD. It is premature to speculate 
on the increase in serum creatinine that would 
require the discontinuation of tolvaptan, since the 
drug is not currently approved for the treatment 
of ADPKD.
Sexton suggests that patients with a total kid-
ney volume of 1500 ml or more may benefit the 
least from tolvaptan, since in such patients vaso-
pressin is less likely to result in a maximum 
urine concentration. This hypothesis would be 
reasonable if the concentrating defect was due to 
reduced production or increased degradation of 
cAMP or decreased protein kinase A activity, since 
tolvaptan is thought to inhibit cyst growth by re-
straining cAMP and protein kinase A signaling. 
However, the concentrating defect in patients 
with ADPKD is probably due to downstream cel-
lular processes or to the reduced efficiency of 
countercurrent exchange caused by disruption of 
the medullary architecture.5 This is consistent 
with the similar reductions (approximately 50%) 
in the rate of growth in total kidney volume that 
was observed in the two groups of patients (total 
kidney volume, <1500 ml or ≥1500 ml), as shown 
in Figure 2B of the article.
We concur with the comments of Jouret and 
Krzesinski regarding urinary tract infection and 
renal cyst infection in patients with ADPKD.
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